An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

Inclusion Criteria: * Signed written consent form. * Healthy male and female participants (not of childbearing potential), determined by no clinically significant deviation from normal in medical history, physical examination, ECGs (electrocardiograms) and clinical laboratory determinations. * Women participants must have documented proof they are not of childbearing potential. * Males sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for duration of treatment with BMS-986177, and for a total of 93 days after the last dose of BMS-986177; and must be willing to refrain from sperm donation during this time. Azoospermic males are exempt from contraceptive requirements. * Normal renal function at screening (Glomerula Filtration Rate ≥ 80 mL/min/1.73 m2. * Body Mass Index (BMI) of 18.0 kg/m2 to 32.0 kg/m2 inclusive. Exclusion Criteria: * Women who are of childbearing potential or breastfeeding. * Any significant acute or chronic illness. * History of gastroesophageal reflux disease, dyspepsia, protracted nausea or chronic diarrhea. * History of upper gastrointestinal ulcer disease within 6 months or current symptomatic or recent gastrointestinal disease that could impact absorption of study treatment. * Abnormal renal profile and/or hematuria (if male) within 3 months of study start. * History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation, or a history of spontaneous bleeding. * Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study. * Donation of blood to a blood bank or in a clinical study (except screening or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for plasma only). * Blood transfusion within 3 months of study treatment administration. * Use of tobacco- or nicotine-containing products (including, but not limited to cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges or nicotine gum) within 6 months prior to study treatment administration. * History of allergy to aspirin or related compounds. Other protocol-defined inclusion/exclusion criteria could apply.